Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer
This study is ongoing, but not recruiting participants.
Study NCT00022191 Information provided by National Cancer Institute (NCI)
First Received: August 10, 2001 Last Updated: July 23, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Bladder Cancer
Urethral Cancer
Additional conditions recognized in this trial
Carcinoma, Transitional Cell
Kidney Neoplasms
Ureteral Neoplasms
Urethral Neoplasms
Urinary Bladder Neoplasms
Urologic Neoplasms
More general conditions related to this trial
Carcinoma
Kidney Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Ureteral Diseases
Urethral Diseases
Urinary Bladder Diseases
Urogenital Neoplasms
Urologic Diseases
Interventions listed in this trial
cisplatin
gemcitabine hydrochloride
paclitaxel
Additional drug interventions recognized in this trial
Gemcitabine
More general drug interventions related to this trial
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Tubulin Modulators
Sponsors listed in this trial
European Organization for Research and Treatment of Cancer
National Cancer Institute (NCI)
Groupe D'Etude des Tumeurs Uro-Genitales
Institute of Cancer Research, United Kingdom
Central European Cooperative Oncology Group
NCIC Clinical Trials Group
Southwest Oncology Group
German Association of Urologic Oncology
Spanish Oncology Genito-Urinary Group
Medical Research Council
Back to top of Main Content
